Usefulness of MRA-DWI mismatch in neuroendovascular therapy for acute cerebral infarction

European Journal of Neurology

Volumn 19, Issue 1, 2012, Pages 114-120

  Deguchi, I ^a   Dembo, T ^a   Fukuoka, T ^a   Nagoya, H ^a   Maruyama, H ^a   Kato, Y ^a   Oe, Y ^a   Horiuchi, Y ^a   Takeda, H ^a   Tanahashi, N ^a  

^a SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

Acute cerebral infarction; Diffusion weighted imaging Alberta Stroke Program Early CT Score; MR angiography diffusion weighted imaging mismatch; Neuroendovascular therapy

Indexed keywords

AGED; ARTERY LESION; ARTICLE; BRAIN INFARCTION; CLINICAL ARTICLE; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; PRIORITY JOURNAL; RANKIN SCALE; REPERFUSION; SCORING SYSTEM; TREATMENT RESPONSE;

AGED; CEREBRAL INFARCTION; DIFFUSION MAGNETIC RESONANCE IMAGING; ENDOVASCULAR PROCEDURES; FEMALE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NEUROSURGICAL PROCEDURES; TREATMENT OUTCOME;

EID: 84155168001     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03444.x     Document Type: Article

References (20)

1. Barber PA, Demchuk AM, Zhang J, et al. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 2000; 355: 1670-1674.
2. Barber PA, Hill MD, Eliasziw M, et al. Imaging of the brain in acute ischaemic stroke: comparison of computed tomography and magnetic resonance diffusion-weighted imaging. J Neurol Neurosurg Psychiatry 2005; 76: 1528-1533.
3. Kimura K, Iguchi Y, Shibazaki K, et al. Large ischemic lesions on diffusion-weighted imaging done before intravenous tissue plasminogen activator thrombolysis predicts a poor outcome in patients with acute stroke. Stroke 2008; 39: 2388-2391.
4. Deguchi I, Takeda H, Furuya D, et al. Significance of magnetic resonance angiography-diffusion weighted imaging mismatch in hyperacute cerebral infarction. J Stroke Cerebrovasc Dis (in press).
5. Deguchi I, Takeda H, Furuya D, et al. Significance of clinical-diffusion mismatch in hyperacute cerebral infarction. J Stroke Cerebrovasc Dis 2011; 20: 62-67.
6. Higashida RT, Furlan AJ. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke 2003; 34: e109-e137.
7. Fiorelli M, Bastianello S, Kummer RV, et al. Hemorrhagic transformation within 36hours of a cerebral infarction: relationships with early clinical deterioration and 30month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke 1999; 30: 2280-2284.
8. Larrue V, Kummer RV, Muller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a Secondary Analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001; 32: 438-441.
9. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007; 38: 967-973.
10. IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004; 35: 904-911.
11. IMS II Traial Investigators. The Interventional Management of Stroke (IMS) II study. Stroke 2007; 38: 2127-2135.
12. Smith WS, Sung G, Saver J, et al. Mechanical thrombectomy for acute ischemic stroke: final Results of the Multi MERCI Trial. Stroke 2008; 39: 1205-1212.
13. Nakagawara J, Minematsu K, Okada Y, et al. Thrombolysis with 0.6mg/kg Intravenous Alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010; 41: 1984-1989.
14. Singer OC, Berkefeld J, Lorenz MW, et al. Risk of symptomatic intracerebral hemorrhage in patients treated with intra-arterial thrombolysis. Cerebrovasc Dis 2009; 27: 368-374.
15. Vora NA, Gupta R, Thomas AJ, et al. Factors predicting hemorrhagic complications after multimodal reperfusion therapy for acute ischemic stroke. AJNR Am J Neuroradial 2007; 28: 1391-1394.
16. Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study. Ann Neurol 2006; 60: 508-517.
17. Davis SM, Donnan GA, Parsons MK, et al. Effects of alteplase beyond 3h after stroke in the echoplanar imaging thrombolytic evaluation trial (EPITHET): a placebo-controlled randomized trial. Lancet Neurol 2008; 7: 299-309.
18. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Traial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36: 66-73.
19. Furlan AJ, Eyding D, Albers GW, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9hours after stroke onset. Stroke 2006; 37: 1227-1231.
20. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischemic stroke selected by MRI perfusion-diffusion-weighted imaging or perfusion CT (DIAS-2): a prospective, randomized, double-blind, placebo-controlled study. Lancet Neurol 2009; 8: 141-150.